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A very signiﬁcant density of adenosine A2A receptors (A2ARs) is present in the striatum,
where they are preferentially localized postsynaptically in striatopallidal medium spiny neu-
rons (MSNs). In this localization A2ARs establish reciprocal antagonistic interactions with
dopamine D2 receptors (D2Rs). In one type of interaction, A2AR and D2R are forming
heteromers and, by means of an allosteric interaction, A2AR counteracts D2R-mediated
inhibitory modulation of the effects of NMDA receptor stimulation in the striatopallidal
neuron. This interaction is probably mostly responsible for the locomotor depressant and
activating effects of A2AR agonist and antagonists, respectively. The second type of inter-
action involves A2AR and D2R that do not form heteromers and takes place at the level
of adenylyl cyclase (AC). Due to a strong tonic effect of endogenous dopamine on striatal
D2R, this interaction keeps A2AR from signaling through AC. However, under conditions of
dopamine depletion or with blockade of D2R, A2AR-mediated AC activation is unleashed
with an increased gene expression and activity of the striatopallidal neuron and with a con-
sequent motor depression.This interaction is probably the main mechanism responsible for
the locomotor depression induced by D2R antagonists. Finally, striatal A2ARs are also local-
ized presynaptically, in cortico-striatal glutamatergic terminals that contact the striato-nigral
MSN.These presynaptic A2ARs heteromerize with A1 receptors (A1Rs) and their activation
facilitates glutamate release. These three different types of A2ARs can be pharmacologi-
cally dissected by their ability to bind ligands with different afﬁnity and can therefore provide
selective targets for drug development in different basal ganglia disorders.
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POSTSYNAPTIC STRIATAL ADENOSINE A2A RECEPTORS
A very signiﬁcant density of adenosine A2A receptors (A2ARs) is
present in the striatum (Rosin et al., 1998; Hettinger et al., 1998;
Schiffmann et al., 2007; Quiroz et al., 2009), where they are pref-
erentially localized postsynaptically in the soma and dendrites of
GABAergic striatopallidal. These neurons also show a high den-
sity of dopamine D2 receptors (D2Rs) and there is clear evidence
for the existence of postsynaptic mechanisms in the control of
glutamatergic neurotransmission to the enkephalinergic medium
spiny neuron (MSN) by at least two reciprocal antagonistic inter-
actions between A2ARs and D2Rs (Ferré et al., 2008). In one type
of interaction, stimulation of A2AR counteracts the D2R-mediated
inhibitory modulation of NMDA receptor (NMDAR)-mediated
effects, which include modulation of Ca2+ inﬂux, transition to
the up-state and neuronal ﬁring (Azdad et al., 2009; Higley and
Sabatini, 2010; Figure 1). This interaction seems to be mostly
responsible for the locomotor depressant and activating effects of
A2ARagonists and antagonists, respectively (Ferré et al., 2008;Orru
et al., 2011), which correlates with the results of behavioral exper-
iments showing that A2AR activation or blockade decreases or
increases, respectively, the motor effects elicited by D2R activation
(Ferré et al., 2008).
Initially, the main mechanism responsible for this A2AR–
D2R interaction was attributed to what it was described as an
“intramembrane interaction,” by which activation of A2AR could
decrease the afﬁnity of an adjacent D2R for agonists in striatal
membrane preparations (Ferré et al., 1991). It was afterward
hypothesized that this kind of intramembrane interaction was
a biochemical property of receptor heteromers with important
functional implications (Zoli et al., 1993). A receptor heteromer is
now deﬁned as a macromolecular complex composed of at least
two (functional) receptor units with biochemical properties that
are demonstrably different from those of its individual compo-
nents (Ferré et al., 2009). The term “intramembrane interaction”
is now known as “allosteric interaction in the receptor heteromer,”
which is deﬁned as an intermolecular interaction bywhich binding
of a ligand to one of the receptor units in the receptor heteromer
changes the binding properties of another receptor unit (Ferré
et al., 2009). Another deﬁnition recently introduced in the ﬁeld
of receptor heteromers is “biochemical ﬁngerprint,” which is a
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FIGURE 1 | Schematic representation of the different subpopulation of striatal A2ARs. Presynaptic A2ARs are localized in glutamatergic terminals that
contact the dynorphynergic medium spiny neuron (DYN-MSN), where they form heteromers with A1Rs. Postsynaptic A2ARs are localized in the enkephalinergic
medium spiny neuron (ENK-MSN), where they from heteromers with D2Rs, CB1Rs, and mGlu5Rs. AC, adenylyl cyclase; EC, endocannabinoid; GLU, glutamate.
biochemical characteristic of a receptor heteromer that can be used
for its identiﬁcation, even in a native tissue (Ferré et al., 2009). The
introductionof this concept is important in viewof thedifﬁculty in
demonstrating receptor heteromers in native tissues. Biophysical
techniques, such as bioluminescence and ﬂuorescence resonance
energy transfer (BRET and FRET) techniques can be easily applied
in artiﬁcial cell systems to demonstrate receptor heteromerization
(Bouvier, 2001), but not in native tissues. Recent technological
advances,using receptor labelingwith selective ﬂuorescent ligands,
have allowed the demonstration of receptor homomers with time-
resolved FRET in a native tissue (oxytocin receptor homomers
in mammary glands; Albizu et al., 2010). However, this required
the use of high quantities of a tissue with high expression of the
receptor under study (Albizu et al., 2010).
The A2AR–D2R allosteric interaction, in fact, constitutes a bio-
chemical ﬁngerprint of the A2AR–D2R heteromer, since it depends
on the proper quaternary structure of the heteromer. Thus, it has
been recently shown that disruption of an electrostatic interaction
between identiﬁed intracellular domains of the A2AR and D2R
leads to a signiﬁcant modiﬁcation of the quaternary structure of
theheteromer and to thedisappearance of theA2AR–D2Rallosteric
interaction (Borroto-Escuela et al., 2010a; Navarro et al., 2010).
The electrostatic interaction in the A2AR–D2R heteromer involves
an arginine-rich epitope of the third intracellular loop (3IL) of the
D2R and a phosphorylated residue localized in the C terminus of
theA2AR (Woods andFerré,2005;Navarro et al., 2010). It is impor-
tant to point out that this electrostatic interaction is not directly
involved in the A2AR–D2R heteromer interface, which seems to be
mostly determined by direct interactions between transmembrane
domains (Borroto-Escuela et al., 2010b; Navarro et al., 2010).
A closer look to recent electrophysiological experiments (Azdad
et al., 2009;Higley and Sabatini, 2010) indicates that, althoughuse-
ful as a biochemical ﬁngerprint, the allosteric interaction in the
receptor heteromer does not play a main role in the antagonistic
A2AR–D2R-mediated functional interaction. In the study byAzdad
et al. (2009), the D2R-mediated response consisted on the coun-
teraction of NMDAR-mediated increase in ﬁring rate by enkepha-
linergic MSNs (analyzed by patch-clamp experiments in identiﬁed
striatal D2R-expressingMSNs). In this experimental setting, appli-
cation of an A2AR agonist did not produce any signiﬁcant effect
on its own, but completely blocked the D2R-mediated response.
Remarkably, this interaction was dependent on the integrity of
the quaternary structure of the A2AR–D2R heteromer. Thus, the
counteracting effect of the A2AR agonist disappeared after the
application of peptides that selectively disrupted the intracellu-
lar electrostatic interaction (Azdad et al., 2009). Importantly, the
counteracting effect of the A2AR agonist was detected in the pres-
ence of a high concentration of the D2R agonist, which should
be able to surmount a decrease in the afﬁnity of the D2R caused
by A2AR occupation (Ferré et al., 1991). Therefore, although it
might still be involved, the allosteric interaction, which leads to a
lower afﬁnity of D2R for dopamine when adenosine is activating
A2AR, does not seem to be the main mechanism underlying the
A2AR–D2R functional interaction in the A2AR–D2R heteromer.
The same intracellular arginine-rich epitope of the D2R that is
involved in the electrostatic interaction with A2AR in the A2AR–
D2R heteromer has been demonstrated to bind to calmodulin
and also to be fundamental for the activation of Gi/o proteins
(Boﬁll-Cardona et al., 2000;Navarro et al., 2009). Since calmodulin
binding to the same epitope of the D2R impairs its ability to signal
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through Gi/o proteins (Boﬁll-Cardona et al., 2000), it is likely that
binding of the C terminus of the A2AR to the same epitope reduces
the capacity of the D2R to bind calmodulin and to signal through
Gi/o proteins. In fact, it has recently been shown that the binding
of calmodulin to the A2AR–D2R heteromer is occurring within
the proximal portion of the A2AR but not with the D2R (Navarro
et al., 2009). It is possible that agonist binding to the A2AR induces
a conformational change in the A2AR–D2R heteromer that causes
an even further impairment in the coupling of the D2R to the Gi/o
protein. Thus, it seems that, in theA2AR–D2Rheteromer,D2Rdoes
not signal through Gi/o proteins or that its main signaling is by
a G-protein-independent mechanism. However, the recent study
by Higley and Sabatini (2010) suggests that the D2R-mediated
inhibitory modulation of NMDAR-mediated Ca2+ signaling in
the enkephalinergic MSN is mediated by PKA and, therefore,most
probably related to the ability of D2R to couple to Gi/o and to
inhibit adenylyl cyclase (AC). Interestingly, in these experiments
(and in agreement with the experiments by Azdad et al., 2009), an
A2AR agonist did not produce any signiﬁcant effect on its own, but
counteracted the effect of a D2R agonist. Thus, although Higley
and Sabatini (2010) suggested that this interaction between A2AR
and D2R takes place at the AC level, it shows similar characteristics
to the A2AR–D2R heteromer-dependent interaction. In summary,
A2AR–D2R heteromers seem to play a key role in the modulation
of NMDAR-mediated signaling in the enkephalinergic MSN, but
the molecular mechanisms involved in these A2AR–D2R–NMDAR
interactions are yet to be determined.
In addition to the antagonistic A2AR–D2R receptor interaction
in the A2AR–D2R heteromer, D2R stimulation impedes A2AR to
signal throughAC (Kull et al., 1999; Chen et al., 2001;Hillion et al.,
2002; Håkansson et al., 2006; Figure 1). This D2R–A2AR interac-
tion takes place at the second messenger level, and stimulation of
Gi/o-coupled D2R counteracts the effects of Gs/olf-coupled A2AR
(Ferré et al., 2007, 2008). Due to a strong tonic effect of endoge-
nous dopamine on striatal D2R, this interaction keeps A2AR from
signaling through AC. However, under conditions of dopamine
depletion or with pharmacological D2R blockade,A2AR-mediated
signaling through the cAMP–PKA cascade may be unleashed.
Antagonism of D2R is biochemically associated with a signiﬁcant
increase in the phosphorylation of PKA-dependent substrates,
which increases gene expression and the activity of the enkepha-
linergic MSN, producing locomotor depression (reviewed in Ferré
et al., 2008). This appears to be the main mechanism responsible
for the locomotor depression induced by D2R antagonists. Thus
the motor depressant and most biochemical effects induced by
pharmacologic blockade of D2R may be counteracted by pharma-
cological blockade of A2AR (Chen et al., 2001; Håkansson et al.,
2006).
The two reciprocal antagonistic interactions,A2AR toward D2R
(A2R–D2R) and D2R toward A2AR (D2R–A2AR), take place simul-
taneously in the same cell, which suggest that are most likely
mediated by the existence of at least two different populations
of postsynaptic striatal A2AR in the enkephalinergic MSN (Ferré
et al., 2008). One population would be forming heteromers with
D2R and would determine that A2AR stimulation inhibits D2R-
mediated signaling (A2AR–D2R interaction), while another pop-
ulation would not be forming heteromers with D2R and would
determine that D2R stimulation inhibits A2AR-mediated signaling
(D2R–A2AR interaction). This second population of postsynaptic
A2AR would either not form heteromers or would form het-
eromers with other receptors, such as glutamate mGlu5 receptors
(mGlu5Rs; Ferré et al., 2002; Figure 1). Importantly, heteromer-
ization of A2AR with mGlu5R is associated with a synergistic effect
upon A2AR and mGlu5R co-activation at the level of AC and
MAPK, providing a physiological mechanism by which A2AR can
overcome theD2R–A2AR interaction (Ferré et al., 2002;Nishi et al.,
2003). Co-stimulation of A2AR and mGlu5R in vivo, with the cen-
tral administration of selective agonists, allowedA2AR to get rid of
the inhibitory effect of theD2R and signal through the cAMP–PKA
cascade (Ferré et al., 2002). Since this A2AR–D2R–mGlu5R inter-
action could be demonstrated in animal models of Parkinson’s
disease (Popoli et al., 2001; Kachroo et al., 2005), it was postulated
that co-administration of A2AR and mGlu5R antagonists could be
useful as a therapeutic strategy in this disease (Popoli et al., 2001).
Still a third population of postsynaptic A2AR would form het-
eromers with cannabinoid CB1 receptors (CB1Rs; Carriba et al.,
2007; Figure 1). In this heteromer, activation of A2AR is necessary
to allow CB1R-mediated signaling. Thus, in a human neuroblas-
toma cell line, CB1R-mediated inhibition of AC activity was found
to be completely dependent on A2AR co-activation (Carriba et al.,
2007). Similarly, several biochemical effects of CB1R agonists in
primary striatal cell cultures and striatal slices have been shown
to depend on A2AR co-activation (Yao et al., 2003; Andersson
et al., 2005). Accordingly, Tebano et al. (2009) reported that the
depression of synaptic transmission induced by a CB1R agonist
in cortico-striatal slices was prevented by A2AR antagonists and
also by the conditional genetic blockade of striatal postsynaptic
A2AR. The permissive effect of A2AR toward CB1R function did
not seem to occur presynaptically, as the ability of the CB1R ago-
nist to increase the R2/R1 ratio under a protocol of paired-pulse
stimulationwas notmodiﬁed by anA2AR antagonist (Tebano et al.,
2009). These results would predict that A2AR antagonists should
produce similar behavioral effects than CB1R antagonists and, in
fact, pharmacological or genetic inactivation of A2ARs reduce the
motor depressant, cataleptic, and rewarding effects of CB1R ago-
nists (Soria et al., 2004; Andersson et al., 2005; Carriba et al., 2007;
Justinova et al., 2011). Signiﬁcantly, it has been recently reported
that low doses of an A2AR antagonist (MSX-3) reduce in squirrel
monkeys self-administration of THC and anandamide, but not
cocaine (Justinova et al., 2011).
Although the studies just mentioned indicate that the motor
(depressant) effects of CB1R agonists might depend on adeno-
sine A2A receptor signaling, a recent study by Lerner et al. (2010)
suggested quite the opposite, that CB1R signaling mediates the
locomotor-activating effects of A2AR antagonists. Thus, pharma-
cological or genetic inactivation of CB1R reduced the locomotor
activation induced by anA2AR antagonist inmice habituated to the
testing environment (Lerner et al., 2010). The mechanistic expla-
nation of this interaction is related to the previously reported D2R
agonist-mediated endocannabinoid release by the enkephaliner-
gic MSN, which by retrograde signaling would inhibit glutamate
release by stimulating CB1R localized in glutamatergic terminals.
This would lead to a decreased stimulation of the striatopallidal
MSN, which would produce locomotor activation (Kreitzer and
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Malenka, 2007). In fact, Kreitzer and Malenka (2007) advocated
that, instead of direct postsynaptic effects, such as the previously
mentioned D2R-mediated modulation of NMDAR-mediated sig-
naling (Azdad et al., 2009; Higley and Sabatini, 2010), this indirect
and endocannabinoid-mediated presynaptic effect is the main
mechanism by which D2R stimulation produces inhibition of the
enkephalinergic MSN function. According to Lerner et al. (2010),
an A2AR antagonist would then produce locomotor activation by
disinhibiting a tonic A2AR-mediated inhibition of D2R-mediated
endocannabinoid release. However, this hypothesis would predict
that CB1R agonists and antagonists should produce locomotor
activation and depression, respectively, and that CB1R blockade
should counteract the motor effects of D2 receptor agonists. This
is the opposite of what has been reported in previous studies (for a
recent review, see Ferré et al., 2010). To reevaluate the ﬁndings by
Lerner et al. (2010)we studied in detail the effects of pharmacolog-
ical interactions between A2AR antagonists and CB1R antagonists
on the locomotor activity in rats not habituated to the testing
environment (Orru et al., submitted). Whereas we could indeed
reproduce the results by Lerner et al. (2010) showing that a CB1R
antagonist signiﬁcantly decreases the locomotor effects induced
by an A2AR antagonist, we found that the CB1R antagonist also
produces a comparable decrease in locomotion in vehicle-treated
animals (statistical analysis indicated that the locomotor effects of
A2AR andCB1R antagonists were not interrelated). It was therefore
the use of habituated animals (which display very low locomotor
activity in the testing environment) what masked the depressant
effect of CB1R antagonist in the vehicle-treated animals in the
study by Lerner et al. (2010).
In addition to the three populations of postsynaptic striatal
A2AR so far reported, there is also experimental evidence for a
potentially more complex picture, which includes the possibility
of receptor heteromultimers. Thus, using a new biophysical/based
technology, sequential resonance energy transfer (SRET), and
bimolecular ﬂuorescence complementation plus BRET, evidence
for A2AR–CB1R–D2R and A2AR–D2R–mGlu5R heteromers in
transfected cells has been recently obtained (Carriba et al., 2008;
Cabello et al., 2009; Navarro et al., 2010). Mutation experiments
indicated that the interactions of the intracellular domains of the
CB1R receptor with A2AR and D2R are fundamental for the cor-
rect formation of the quaternary structure needed for the function
(MAPK signaling) of the A2AR–CB1R–D2R heteromers. It should
be noted that the analysis of MAPK signaling in striatal slices of
CB1R KO mice and wild-type littermates supports the existence
of A2AR–CB1R–D2R receptor heteromers in the brain (Navarro
et al., 2010). Despite the stoichiometry of the different popula-
tions of postsynaptic striatal A2AR heteromers (and homomers)
is not known, taking into account the very high density of A2ARs
and D2Rs in the enkephalinergic MSM, we postulate that A2AR
and D2R homomers and A2AR–D2R heteromers are the most
common receptor populations, followed by combinations of those
populations with CB1R and mGlu5R.
It is also of importance to mention that there is also evidence
for the existence of A2AR receptors, also co-localized with D2Rs,
in the somatodendritic and nerve terminal regions of the cholin-
ergic striatal interneurons and that their interactions modulate
acetylcholine release (James and Richardson, 1993; Jin et al., 1993;
Preston et al., 2000; Tozzi et al., 2011). The study by Jin et al.
(1993) showed evidence for an antagonistic A2AR–D2AR inter-
action in the modulation of striatal acetylcholine release. Thus,
A2AR stimulation counteracted the ability of D2R activation to
inhibit acetylcholine release. Similarly, a recent study showed that
A2AR blockade potentiates D2R-mediated modulation of acetyl-
choline release (Tozzi et al., 2011), again indicating the existence of
an antagonistic A2AR–D2R interaction and, probably, A2AR–A2AR
heteromers in striatal cholinergic interneurons.
PRESYNAPTIC STRIATAL ADENOSINE A2A RECEPTORS
Striatal A2ARs are not only localized postsynaptically but also
presynaptically, in glutamatergic terminals,where they heteromer-
ize with A1 receptors (A1Rs) and where they perform a ﬁne-tuned
modulation of glutamate release (Ciruela et al., 2006; Quiroz et al.,
2009; Figure 1). Thus, A1R–A2AR heteromers seem to work as a
concentration-dependent switch (Ferré et al., 2007), with adeno-
sine acting primarily at A1Rs at low concentrations, and at both
A1Rs andA2ARs at higher concentrations. Activation of theA1R in
theA1R–A2ARheteromerproduces inhibitionof glutamate release,
while the additional activation of the A2AR produces the oppo-
site effect, on a mechanism that seems to involve an allosteric
modulation in the receptor heteromer and interactions at the G
protein level (Ciruela et al., 2006; Ferré et al., 2007). Interestingly,
presynapticA2ARs are preferentially localized in glutamatergic ter-
minals of cortico-striatal afferents to the dynorphinergic MSN
(Quiroz et al., 2009). Apart from morphological evidence pro-
vided by immunohistochemical and electron microscopy experi-
ments, patch-clamp experiments in identiﬁed enkephalinergic and
dynorphinergic MSNs provided a functional demonstration of
the segregation of striatal presynaptic A2ARs. Thus, an A2AR ago-
nist and an A2AR receptor antagonist signiﬁcantly increased and
decreased, respectively, the amplitude of excitatory postsynaptic
currents induced by the intrastriatal stimulation of glutamatergic
afferents measured in identiﬁed enkephalinergic, but not dynor-
phinergic MSNs. Mean-variance analysis indicated a presynaptic
locus for the A2AR-mediated modulation (Quiroz et al., 2009).
Thus, there seems to be a selective A2AR-mediated modulation of
glutamate release to the dynorphinergicMSN,which is in disagree-
ment with the recently proposed role of postsynaptic A2ARs in
the modulation of glutamate release to the enkephalinergic MSN
(Lerner et al., 2010).
The powerful modulatory role of presynaptic A2ARs on striatal
glutamate releasewas ﬁrst demonstratedwith in vivo microdialysis
experiments by Popoli et al. (1995), who showed that the striatal
perfusionof anA2ARagonist produced a very pronounced increase
in the basal striatal extracellular concentrations of glutamate. Also
intrastriatal perfusion of anA2AR antagonist through a microdial-
ysis probe could signiﬁcantly counteract striatal glutamate release
induced by cortical electrical stimulation in the orofacial premo-
tor cortex (Quiroz et al., 2009). A striking unexpected ﬁnding was
that the counteraction of glutamate release was also accompanied
by a complete counteraction of the jaw movements induced by
the cortical electrical stimulation, demonstrating the very impor-
tant role of presynaptic A2ARs in the control of cortico-striatal
glutamatergic neurotransmission. By combining cortical electri-
cal stimulation and recording of EMG activity of the mastication
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muscles, a power correlation coefﬁcient (PCC)was established as a
quantitative in vivo measure of cortico-striatal neurotransmission
(Quiroz et al., 2009). PCC was shown to be signiﬁcantly and dose
dependently decreased by the systemic administration of an A2AR
receptor antagonist. PCC could therefore be used as a method to
screen the presynaptic effect of A2AR antagonists (see below).
According to the widely accepted functional basal circuitry
model (Obeso et al., 2002; DeLong and Wichmann, 2007), block-
ade of postsynaptic striatal A2AR in the A2AR–D2R heteromer,
localized in the enkephalinergic MSN should potentiate spon-
taneous or psychostimulant-induced motor activation. On the
other hand, according to the same model, blockade of presynaptic
striatal A2AR localized in the cortico-striatal glutamatergic termi-
nals that make synaptic contact with the dynorphinergic MSN
should decrease motor activity. The clear locomotor-activating
effects of systemically administered A2AR antagonists could be
explained by the signiﬁcantly higher density of postsynaptic ver-
sus presynaptic striatal A2AR and to a stronger inﬂuence of a tonic
adenosine andA2AR-mediated modulation of the enkephalinergic
versus dynorphinergic MSNs under basal conditions. The results
by Shen et al. (2008) about the differential effects of A2AR antag-
onists on psychostimulant-induced locomotor activation in WT
versus conditional striatal postsynaptic A2AR KO mice (potenti-
ation versus counteraction, respectively) support this hypothesis.
As previously suggested (Ferré et al., 2007), activation of presynap-
tic A2ARs seems to be highly dependent on the level of adenosine
generated upon cortico-striatal glutamatergic input.
Striatal D2Rs are also localized presynaptically, in dopamin-
ergic and glutamatergic terminals (Higley and Sabatini, 2010),
giving the frame for the existence of interactions with A2ARs at
least in those terminals establishing contact with the dynorphin-
ergic MSN. The experimental evidence suggest that there is also
a presynaptic D2R–A2AR interaction by which D2R activation
tonically inhibits the ability of endogenous adenosine to pro-
duce an A2AR-mediated increase in the basal extracellular levels of
glutamate. Thus, dopamine denervation signiﬁcantly potentiates
A2AR agonist-mediated stimulation of glutamate release (Tan-
ganelli et al., 2004). This has the biochemical characteristics of
an interaction between A2ARs and D2Rs at the AC level and not
forming A2AR–D2R heteromers. Furthermore, results Rodrigues
et al. (2005) have also demonstrated the existence of mGlu5Rs
in striatal glutamatergic terminals co-localized with A2ARs and
which facilitate glutamate release in a synergistic manner. The
interplay between adenosine- and dopamine-mediated actions at
the presynaptic level is therefore affected by the occurrence of
mGlu5Rs.
The presynaptic localization of CB1Rs in striatal glutamater-
gic terminals is well established, and therefore they can be co-
localized with A2AR in terminals establishing contact with the
dynorphinergic MSN (Ferré et al., 2010). The existence of A2AR–
CB1R heteromers in striatal glutamatergic terminals which could
mediate the reinforcing effects of cannabinoids has been recently
postulated (Ferré et al., 2010; Justinova et al., 2011). However,
a recent study by Martire et al. (2011) indicates that cannabi-
noid/adenosine functional interactions result from an interaction
at the second messenger level. In the frame of heteromeriza-
tion A2AR activation should facilitate the Gi/o-mediated effect
of CB1R activation measured, as inhibition of glutamate release.
Nevertheless, Martire et al. (2011), by studying extracellular ﬁeld
potentials recordings in cortico-striatal slices and superfused stri-
atal nerve terminals, very convincingly showed that, instead,
A2AR activation prevents CB1R-mediated inhibition of glutamate
release. These results indicate that regulation of glutamate release
by cannabinoids is not dependent on presynaptic A2AR–CB1R
heteromers.
In summary, a great amount of available data indicates that,
presynaptically, A2ARs form heteromers mostly with A1Rs. In
addition, there seems to be a population of A2ARs not forming
heteromers but establishing antagonistic interactions with D2Rs
and CB1Rs and synergistic interactions with mGlu5Rs. Apart from
co-expression, at this moment we do not know the variables that
determine the ability of A2ARs to bind to different receptors to
form different pre and postsynaptic heteromers. Thus, D2Rs are
also localized presynaptically, but yet they do not seem to form
heteromers with A2ARs. A2ARs could bind with more afﬁnity to
A1Rs than to D2Rs or particular scaffolding proteins could favor a
particular A2AR heteromer. All these are questions still need to be
answered.
TARGETING STRIATAL PRE AND POSTSYNAPTIC A2A
RECEPTORS
A surprising yet fundamental ﬁnding of a recent study is that
several A2AR antagonists previously thought as being pharma-
cologically similar present different striatal pre and postsynaptic
proﬁles (Orru et al., 2011). Six compounds already known as selec-
tive A2AR antagonists were ﬁrst screened for their ability to block
striatal pre and postsynaptic A2ARs with in vivo models. Loco-
motor activation was used to evaluate postsynaptic activity while
PCC counteractionwas used to determine presynaptic activity (see
above). SCH-442416 and KW-6002, showed preferential pre and
postsynaptic proﬁles, respectively, and four compounds, MSX-3,
SCH-420814, SCH-58261, and ZM-241385, showed mixed pre–
postsynaptic proﬁles. Combining in vivo microdialysis with cor-
tical electrical stimulation was used as an additional in vivo eval-
uation of presynaptic activity of A2AR antagonists. In agreement
with its preferential presynaptic proﬁle, SCH-442416 signiﬁcantly
counteracted striatal glutamate release induced by cortical stim-
ulation at a dose that strongly counteracted PCC but did not
induce locomotor activation. On the other hand, according to
its preferential postsynaptic proﬁle, KW-6002 did not modify stri-
atal glutamate release induced by cortical stimulation at a dose
that produced a pronounced locomotor activation but did not
counteract PCC.
Another important ﬁnding of the study by Orru et al. (2011)
was that at least part of these pharmacological differences between
A2AR antagonists could be explained by the ability of pre and post-
synaptic A2AR to form different receptor heteromers, with A1R
and D2R, respectively (see above). Radioligand-binding experi-
ments were performed in cells stably expressing A2AR, A2AR–D2R
heteromers,orA1R–A2ARheteromers to determine possible differ-
ences in the afﬁnity of these different A2ARs for A2AR antagonists.
Co-expression with A1R did not signiﬁcantly modify the afﬁnity
of A2ARs for the different ligands, but co-expression with D2Rs
decreased the afﬁnity of all compounds, with the exception of
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KW-6002 (Orru et al., 2011). The structural changes in the A2AR
induced by heteromerization with the D2R could be detected not
only by antagonists but also by agonist binding. Indeed, the afﬁn-
ity of the selective A2AR agonist CGS-21680 was reduced in cells
co-transfected with D2Rs. When trying to explain the differential
action of SCH-442416 observed in vivo, it is interesting to note that
this compound in particular showed a much higher afﬁnity for the
A2AR in a presynaptic-like than in a postsynaptic-like context. In
fact, the afﬁnity of A2AR for SCH-442416 in cells expressingA2AR–
D2Rheteromerswasmarkedly reduced (40 times higher B50 values
in competitive-inhibition experiments with [3H]ZM-241385 in
cells expressing A2AR–D2R than A1R–A2AR heteromers).
The decrease in afﬁnity upon co-expression with D2Rs was
much less pronounced for ZM-241385, SCH-58261, MSX2, or
SCH-420814, for which the afﬁnity was reduced from two to about
ninefold (Orru et al., 2011). Taking into account that these A2AR
antagonists behaved qualitatively similar than the A2AR agonist
CGS-21680 in terms of binding to A1R–A2AR and A2AR–D2R
heteromers, it was expected that these four compounds com-
pete equally for the binding of the endogenous agonist at pre
and at postsynaptic sites. This would ﬁt with the in vivo data,
which showed that these compounds have a non-preferred pre–
postsynaptic proﬁle. Yet, KW-6002 was the only antagonist whose
afﬁnity was not signiﬁcantly different in cells expressing A2AR,
A1R–A2AR heteromers, or A2AR–D2R heteromers. Thus, KW-
6002 showed the best relative afﬁnity for A2AR–D2R heteromers
of all compounds, which can at least partially explain its pref-
erential postsynaptic proﬁle. Experiments performed with the
non-selective adenosine receptor antagonist caffeine also showed
a correlation between the in vivo data and the in vitro preference
for postsynaptic A2AR-containing heteromers. It was previously
reported that in transfected mammalian cells the afﬁnity of A2AR
for the non-selective adenosine receptor antagonist caffeine did
not change when co-transfected with D2R, but it was signiﬁcantly
decreased (about 10 times) when co-transfected with A1R (Ciru-
ela et al., 2006). As predicted, caffeine did not signiﬁcantly reduce
PCCat doses that produce pronouncedmotor activation (Zanoveli
et al., in preparation).
It must be pointed out that to say that SCH-442416 is a selec-
tive presynaptic A2AR antagonist is an oversimpliﬁcation. In fact,
the in vitro data indicated that SCH-442416 binds equally well to
the A2AR not forming heteromers than to the A2AR in the A1R–
A2AR heteromer. Therefore, according to the previous description
of the different populations of striatal A2ARs, SCH-442416 should
also be effective at counteracting D2R antagonist-induced motor
depression. In fact, at doses that are not producing locomotor
activation (but that reduce PCC), SCH-442416 signiﬁcantly coun-
teracts the locomotor depression induced by the D2R antagonist
raclopride (Orru et al., submitted). On the other hand, KW-6002
produced the same locomotor activation with or without co-
administration with raclopride, in agreement with its ability to
block the three populations of A2AR studied so far in vitro, A2AR,
A2A–D2R, and A1R–A2AR. Importantly, KW-6002 also produced
the same locomotor activation when co-administered with the
A2AR agonist CGS-21680, while SCH-442416, at the same dose
that counteracted the depressant effect of raclopride, did not sig-
niﬁcantly counteract the depressant effect of CGS-21680. These
results, therefore agree with the hypothesis that the subpopu-
lation of postsynaptic A2AR forming heteromers with D2R are
mainly responsible for both the locomotor activation and depres-
sion induced by A2AR antagonists and agonists, respectively. In
summary, SCH-442416 can be considered as a compound that at
relatively low doses not only binds preferentially to presynaptic
A2ARs localized in cortico-striatal glutamatergic terminals (Orru
et al., 2011), but also to a subpopulation of postsynaptic A2ARs
most probably not forming heteromers with D2Rs, but which
function is tonically inhibited by D2Rs activated by endogenous
dopamine. Interestingly, [11C]SCH-442416 has been used in rats,
monkeys, and humans as a PET radioligand and shown to nicely
label striatal A2ARs (Moresco et al., 2005; Schiffmann et al., 2007;
Brooks et al., 2010). The low doses used in PET experiments indi-
cate that [11C]SCH-442416 is mostly labeling presynaptic A2ARs
and postsynaptic A2ARs that do not form heteromers with D2Rs.
The use of [11C]SCH-442416 and other less selective radioligand
in combination with cold SCH-442416 could allow the identiﬁca-
tion of the different populations of A2ARs in the human brain. The
picture is still incomplete, and a further evaluation of the afﬁnity
of A2AR antagonists forA2AR–mGlu5R andA2AR–CB1 heteromers
(and of heterotrimers) is needed. Nevertheless, the information so
far available is very valuable to attempt the design of more efﬁcient
A2AR antagonists to be used in basal ganglia disorders.
A2A RECEPTOR HETEROMERS AS TARGETS FOR DRUG
DEVELOPMENT
The results of the abovementioned studies support the notion that
receptor heteromersmay be used as selective targets for drug devel-
opment. Main reasons are the very speciﬁc neuronal localization
of receptor heteromers (even more speciﬁc than receptor subtypes
themselves), and a differential ligand afﬁnity of a receptor depend-
ing on its partner (or partners) in the receptor heteromer. Striatal
A2AR-containing heteromers become particularly interesting tar-
gets, eventually useful for a variety of neuropsychiatric disorders.
Blocking postsynaptic A2ARs in the enkephalinergic MSN should
be beneﬁcial for Parkinson’s disease because it would decrease the
activity of the indirect striatal efferent pathway. On the one hand,
one beneﬁt would come from potentiating the effect of l-dopa or
other dopamine receptor agonists on the D2R-mediated signal-
ing in the A2AR–D2R heteromer. On the other hand, blockade of
A2ARs not forming heteromers with D2Rs (but antagonistically
interacting with D2R at the AC level) should counteract the effects
of the disinhibited A2AR signaling. However, blocking presynaptic
A2AR in glutamatergic terminals contacting dynorphinergic MSN
(either forming or not heteromers with A1R) should decrease
glutamatergic transmission through the direct striatal efferent
pathway, thus decreasing motor activity and, therefore, decreas-
ing the antiparkinsonian efﬁcacy of A2AR antagonists. The most
convenient A2AR antagonist to treat Parkinson’s disease patients
would have more afﬁnity for postsynaptic than for presynaptic
receptors. Additionally, a selective blockade of presynaptic A2ARs
should be useful in dyskinetic disorders such as Huntington’s dis-
ease and could also be useful in obsessive–compulsive disorders
and drug addiction. Effective treatment of l-dopa-induced dyski-
nesia using “presynaptic”A2AR antagonists would be a possibility
to explore.
Frontiers in Neuroanatomy www.frontiersin.org June 2011 | Volume 5 | Article 36 | 6
Ferré et al. Striatal adenosine A2A receptors
The results by Orru et al. (2011) give a mechanistic explanation
to the already reported antiparkinsonian activity of KW-6002
and suggest that SCH-442416 could be useful for the treat-
ment of dyskinetic disorders, obsessive–compulsive disorders and
in drug addiction. Medicinal chemistry and in silico modeling
should help in elucidating the molecular properties that deter-
mine the particular pharmacological proﬁle of SCH-442416 and
KW-6002, which may be used as lead compounds to obtain,
respectively, more effective antidyskinetic and antiparkinsonian
compounds.
ACKNOWLEDGMENTS
Work supported with the intramural funds of the National
Institute on Drug Abuse.
REFERENCES
Albizu, L., Cottet, M., Kralikova, M.,
Stoev, S., Seyer, R., Brabet, I., Roux,
T., Bazin, H., Bourrier, E., Lamar-
que, L., Breton, C., Rives, M. L.,
Newman, A., Javitch, J., Trinquet,
E., Manning, M., Pin, J. P., Mouil-
lac, B., and Durroux, T. (2010).
Time-resolved FRET between
GPCR ligands reveals oligomers in
native tissues. Nat. Chem. Biol. 6,
587–594.
Andersson, M., Usiello, A., Borgkvist,
A., Pozzi, L., Dominguez, C., Fien-
berg, A. A., Svenningsson, P., Fred-
holm, B. B., Borrelli, E., Greengard,
P., and Fisone, G. (2005). Cannabi-
noid action depends on phospho-
rylation of dopamine- and cAMP-
regulated phosphoprotein of 32 kDa
at the protein kinase A site in striatal
projection neurons. J. Neurosci. 25,
8432–8438.
Azdad, K., Gall, D., Woods, A. S.,
Ledent, C., Ferré, S., and Schiff-
mann, S. N. (2009). Dopamine
D2 and adenosine A2A recep-
tors regulate NMDA-excitation in
accumbens neurons through A2A-
D2 receptor heteromerization. Neu-
ropsychopharmacology 34, 972–986.
Boﬁll-Cardona, E., Kudlacek, O., Yang,
Q., Ahorn, H., Freissmuth, M.,
and Nanoff, C. (2000). Binding of
calmodulin to the D2-dopamine
receptor reduces receptor signaling
by arresting the G protein acti-
vation switch. J. Biol. Chem. 275,
32672–32680.
Borroto-Escuela, D. O., Marcellino, D.,
Narvaez,M., Flajolet,M.,Heintz, N.,
Agnati, L., Ciruela, F., and Fuxe, K.
(2010a). A serine point mutation
in the adenosine A2AR C-terminal
tail reduces receptor heteromeriza-
tion and allostericmodulation of the
dopamine D2R. Biochem. Biophys.
Res. Commun. 394, 222–227.
Borroto-Escuela, D. O., Romero-
Fernandez, W., Tarakanov, A.
O., Gómez-Soler, M., Corrales,
F., Marcellino, D., Narvaez, M.,
Frankowska, M., Flajolet, M.,
Heintz, N., Agnati, L. F., Ciruela, F.,
and Fuxe, K. (2010b). Characteri-
zation of the A2AR-D2R interface:
focus on the role of the C-terminal
tail and the transmembrane helices.
Biochem. Biophys. Res. Commun.
402, 801–807.
Bouvier, M. (2001). Oligomerization
of G-protein-coupled transmitter
receptors. Nat. Rev. Neurosci. 2,
274–286.
Brooks, D. J., Papapetropoulos, S., Van-
denhende, F., Tomic, D., He, P., Cop-
pell, A., and O’Neill, G. (2010).
An open-label, positron emission
tomography study to assess adeno-
sine A2A brain receptor occupancy
of vipadenant (BIIB014) at steady-
state levels in healthy male vol-
unteers. Clin. Neuropharmacol. 33,
55–60.
Cabello, N., Gandia, J., Bertarelli, D.
C., Watanabe, M., Lluis, C., Franco,
R., Ferré, S., Lujan, R., and Ciruela,
F. (2009). Metabotropic glutamate
type 5, dopamine D2 and adeno-
sine A2A receptors form higher-
order oligomers in living cells. J.
Neurochem. 109, 1497–1507.
Carriba, P., Navarro, G., Ciruela, F.,
Ferré, S., Casado, V., Agnati, L.
F., Cortes, A., Mallol, J., Fuxe, K.,
Canela, E. I., Lluis, C., and Franco,
R. (2008). Detection of heteromer-
ization of more than two pro-
teins by sequential BRET-FRET. Nat.
Methods 5, 727–733.
Carriba, P., Ortiz, O., Patkar, K., Justi-
nova, Z., Stroik, J., Themann, A.,
Müller, C.,Woods, A. S., Hope, B. T.,
Ciruela, F., Casadó, V., Canela, E. I.,
Lluis, C., Goldberg, S. R., Moratalla,
R., Franco, R., and Ferré, S. (2007).
Striatal adenosine A2A and cannabi-
noid CB1 receptors form functional
heteromeric complexes that medi-
ate the motor effects of cannabi-
noids.Neuropsychopharmacology 32,
2249–2259.
Chen, J. F., Moratalla, R., Impagnatiello,
F., Grandy, D. K., Cuellar, B., Rubin-
stein, M., Beilstein, M. A., Hackett,
E., Fink, J. S., Low, M. J., Ongini,
E., and Schwarzschild, M. A. (2001).
The role of the D(2) dopamine
receptor (D(2)R) in A(2A) adeno-
sine receptor (A(2A)R)-mediated
behavioral and cellular responses as
revealed byA(2A) and D(2) receptor
knockout mice. Proc. Natl. Acad. Sci.
U.S.A. 98, 1970–1975.
Ciruela, F., Casado, V., Rodrigues, R. J.,
Luján, R., Burgueno, J., Canals, M.,
Borycz, J., Rebola, N., Goldberg, S.
R., Mallol, J., Cortés, A., Canela, E.
I., López-Giménez, J. F.,Milligan,G.,
Lluis, C., Cunha, R. A., Ferré, S., and
Franco, R. (2006). Presynaptic con-
trol of striatal glutamatergic neuro-
transmission by adenosine A1-A2A
receptor heteromers. J. Neurosci. 26,
2080–2087.
DeLong, M. R., and Wichmann, T.
(2007).Circuits and circuit disorders
of the basal ganglia. Arch. Neurol. 64,
20–24.
Ferré, S., Baler, R., Bouvier, M., Caron,
M. G., Devi, L. A., Durroux, T.,
Fuxe, K., George, S. R., Javitch, J.
A., Lohse, M. J., Mackie, K., Milli-
gan, G., Pﬂeger, K. D. G., Pin, J.-P.,
Volkow, N., Waldhoer, M., Woods,
A. S., and Franco, R. (2009). Build-
ing a new conceptual framework
for receptor heteromers. Nat. Chem.
Biol. 5, 131–134.
Ferré, S., Ciruela, F., Woods, A. S., Lluis,
C., and Franco, R. (2007). Func-
tional relevance of neurotransmitter
receptor heteromers in the central
nervous system. Trends Neurosci. 30,
440–446.
Ferré, S., Karcz-Kubicha, M., Hope,
B. T., Popoli, P., Burgueno, J.,
Casado, V., Fuxe, K., Lluis, C., Gold-
berg, S. R., Franco, R., and Ciru-
ela, F. (2002). Synergistic interac-
tion between adenosine A2A and
glutamate mGlu5 receptors: impli-
cations for striatal neuronal func-
tion. Proc. Natl. Acad. Sci. U.S.A. 99,
11940–11945.
Ferré, S., Lluis, C., Justinova, Z., Quiroz,
C., Orru, M., Navarro, G., Canela,
E. I., Franco, R., and Goldberg, S.
R. (2010). Adenosine-cannabinoid
receptor interactions. Implications
for striatal function. Br. J. Pharma-
col. 160, 443–453.
Ferré, S., Quiroz, C., Woods, A. S.,
Cunha, R., Popoli, P., Ciruela, F.,
Lluis, C., Franco, R., Azdad, K., and
Schiffmann, S. N. (2008). An update
on adenosine A2A-dopamine D2
receptor interactions. Implications
for the function of G protein-
coupled receptors. Curr. Pharm. Des.
14, 1468–1474.
Ferré, S., von Euler, G., Johansson,
B., Fredholm, B. B., and Fuxe, K.
(1991). Stimulation of high afﬁnity
adenosine A-2 receptors decreases
the afﬁnity of dopamine D-2 recep-
tors in rat striatal membranes.
Proc. Natl. Acad. Sci. U.S.A. 88,
7238–7241.
Håkansson, K., Galdi, S., Hendrick, J.,
Snyder,G.,Greengard,P., andFisone,
G. (2006). Regulation of phospho-
rylation of the GluR1 AMPA recep-
tor by dopamine D2 receptors. J.
Neurochem. 96, 482–488.
Hettinger, B. D., Lee, A., Linden, J., and
Rosin, D. L. (1998). Ultrastructural
localization of adenosineA2A recep-
tors suggests multiple cellular sites
for modulation of GABAergic neu-
rons in rat striatum. J. Comp. Neurol.
431, 331–346.
Higley, M. J., and Sabatini, B. L. (2010).
Competitive regulation of synap-
tic Ca2( inﬂux by D2 dopamine
and A2A adenosine receptors. Nat.
Neurosci. 13, 958–966.
Hillion, J., Canals, M., Torvinen, M.,
Casado, V., Scott, R., Terasmaa,
A., Hansson, A., Watson, S., Olah,
M. E., Mallol, J., Canela, E. I.,
Zoli, M., Agnati, L. F., Ibanez, C.
F., Lluis, C., Franco, R., Ferré, S.,
and Fuxe, K. (2002). Coaggrega-
tion, cointernalization and codesen-
sitization of adenosineA2A receptors
and dopamine D2 receptors. J. Biol.
Chem. 277, 18091–18097.
James, S., and Richardson, P. J. (1993).
The subcellular distribution of
[3H]-CGS 21680 binding sites
in the rat striatum: copuriﬁ-
cation with cholinergic nerve
terminals. Neurochem. Int. 23,
115–122.
Jin, S., Johansson, B., and Fredholm,
B. B. (1993). Effects of adenosine
A1 and A2 receptor activation on
electrically evoked dopamine and
acetylcholine release from rat striatal
slices. J. Pharmacol. Exp. Ther. 267,
801–808.
Justinova, Z., Ferré, S., Redhi, G. H.,
Mascia, P., Stroik, J., Quarta, D.,
Yasar, S., Muller, C. E., Franco,
R., and Goldberg, S. R. (2011).
Reinforcing and neurochemical
effects of cannabinoid CB1 recep-
tor agonists, but not cocaine,
are altered by an adenosine A2A
receptor antagonist. Addict. Biol. 16,
405–415.
Frontiers in Neuroanatomy www.frontiersin.org June 2011 | Volume 5 | Article 36 | 7
Ferré et al. Striatal adenosine A2A receptors
Kachroo, A., Orlando, L. R., Grandy, D.
K., Chen, J. F., Young, A. B., and
Schwarzschild, M. A. (2005). Inter-
actions betweenmetabotropic gluta-
mate 5 and adenosine A2A receptors
in normal and parkinsonian mice. J.
Neurosci. 25, 10414–10419.
Kreitzer, A. C., and Malenka, R. C.
(2007). Endocannabinoid-mediated
rescue of striatal LTD and motor
deﬁcits in Parkinson’s disease mod-
els. Nature 445, 643–647.
Kull, B., Ferré, S., Arslan, G., Svennings-
son, P., Fuxe, K., Owman, C., and
Fredholm, B. B. (1999). Recipro-
cal interactions between adenosine
A2A and dopamine D2 receptors in
CHO cells co-transfected with the
two receptors. Biochem. Pharmacol.
58, 1035–1045.
Lerner, T. N., Horne, E. A., Stella, N.,
and Kreitzer, A. C. (2010). Endo-
cannabinoid signaling mediates psy-
chomotor activation by adenosine
A2A antagonists. J. Neurosci. 30,
2160–2164.
Martire, A., Tebano, M. T., Chiodi, V.,
Ferreira, S. G., Cunha, R. A., Köfalvi,
A., and Popoli, P. (2011). Pre-
synaptic adenosine A2A receptors
control cannabinoid CB1 receptor-
mediated inhibition of striatal glu-
tamatergic neurotransmission. J.
Neurochem. 116, 273–280.
Moresco, R. M., Todde, S., Belloli, S.,
Simonelli, P., Panzacchi, A., Riga-
monti, M., Galli-Kienle, M., and
Fazio, F. (2005). In vivo imag-
ing of adenosine A2A receptors
in rat and primate brain using
[11C]SCH442416. Eur. J. Nucl. Med.
Mol. Imaging 32, 405–413.
Navarro, G., Aymerich, M. S., Mar-
cellino, D., Cortes, A., Casado, V.,
Mallol, J., Canela, E. I., Agnati,
L. F., Woods, A. S., Fuxe, K.,
Lluis, C., Lanciego, J. L., Ferré, S.,
and Franco, R. (2009). Interactions
between calmodulin, adenosineA2A
and dopamine D2 receptors. J. Biol.
Chem. 284, 28058–28068.
Navarro, G., Ferré, S., Cordomi, A.,
Moreno, E., Mallol, J., Casadó, V.,
Cortés, A., Hoffmann, H., Ortiz, J.,
Canela, E. I., Lluís, C., Pardo, L.,
Franco, R., and Woods, A. S. (2010).
Interactions between intracellular
domains as key determinants of the
quaternary structure and functionof
receptor heteromers. J. Biol. Chem.
285, 27346–27359.
Nishi, A., Liu, F., Matsuyama, S.,
Hamada, M., Higashi, H., Nairn,
A. C., and Greengard, P. (2003).
Metabotropic mGlu5 receptors reg-
ulate adenosineA2A receptor signal-
ing. Proc. Natl. Acad. Sci. U.S.A. 100,
1322–1327.
Obeso, J. A., Rodríguez-Oroz, M.
C., Rodríguez, M., Arbizu, J., and
Giménez-Amaya, J. M. (2002).
The basal ganglia and disorders
of movement: pathophysiological
mechanisms. News Physiol. Sci. 17,
51–55.
Orru, M., Bakešová, J., Brugarolas, M.,
Quiroz, C., Beaumont, V., Goldberg,
S. R, Lluís, C., Cortés, A., Franco,
R., Casadó, V., Canela, E. I., and
Ferré, S. (2011). Striatal pre- and
postsynaptic proﬁle of adenosine
A(2A) receptor antagonists. PLoS
ONE 6, e16088. doi: 10.1371/jour-
nal.pone.0016088
Popoli, P., Betto, P., Reggio, R., and
Ricciarello, G. (1995). Adenosine
A2A receptor stimulation enhances
striatal extracellular glutamate lev-
els in rats. Eur. J. Pharmacol. 287,
215–217.
Popoli, P., Pezzola, A., Torvinen, M.,
Reggio, R., Pintor, A., Scarchili,
L., Fuxe, K., and Ferré, S.
(2001). The selective mGlu5
receptor agonist CHPG inhibits
quinpirole-induced turning in
6-hydroxydopamine-lesioned rats
and modulates the binding charac-
teristics of dopamine D2 receptors
in the rat striatum: interactions
with adenosine A2A receptors.
Neuropsychopharmacology 25,
505–513.
Preston, Z., Lee, K., Widdowson, L.,
Freeman, T. C., Dixon, A. K., and
Richardson, P. J. (2000). Adenosine
receptor expression and function in
rat striatal cholinergic interneurons.
Br. J. Pharmacol. 130, 886–890.
Quiroz, C., Lujan, R., Uchigashima, M.,
Simoes, A. P., Lerner, T. N., Borycz,
J., Kachroo, A., Canas, P. M., Orru,
M., Schwarzschild, M. A., Rosin, D.
L., Kreitzer, A. C., Cunha, R. A.,
Watanabe, M., and Ferré, S. (2009).
Key modulatory role of presynaptic
adenosine A2A receptors in corti-
cal neurotransmission to the striatal
direct pathway. ScientiﬁcWorldJour-
nal 9, 1321–1344.
Rodrigues, R. J., Alfaro, T. M., Rebola,
N., Oliveira, C. R., and Cunha R.
A. (2005). Co-localization and func-
tional interaction between adeno-
sine A(2A) and metabotropic group
5 receptors in glutamatergic nerve
terminals of the rat striatum. J. Neu-
rochem. 92, 433–441.
Rosin,D. L., Robeva,A.,Woodard, R. L.,
Guyenet, P. G., and Linden, J. (1998).
Immunohistochemical localization
of adenosine A2A receptors in the
rat central nervous system. J. Comp.
Neurol. 401, 163–186.
Schiffmann, S. N., Fisone, G., Moresco,
R., Cunha, R., and Ferré, S. (2007).
Adenosine A2A receptors and basal
ganglia physiology. Prog. Neurobiol.
83, 277–292.
Shen, H. Y., Coelho, J. E., Ohtsuka,
N., Canas, P. M., Day, Y. J., Huang,
Q. Y., Rebola, N., Yu, L., Boison,
D., Cunha, R. A., Linden, J., Tsien,
J. Z., and Chen, J. F. (2008). A
critical role of the adenosine A2A
receptor in extrastriatal neurons
in modulating psychomotor activ-
ity as revealed by opposite pheno-
types of striatum and forebrain A2A
receptor knock-outs. J. Neurosci. 28,
2970–2975.
Soria, G., Castañé, A., Ledent, C., Par-
mentier, M., Maldonado, R., and
Valverde, O. (2004). Adenosine A2A
receptors are involved in physical
dependence and place conditioning
induced by THC. Eur. J. Neurosci. 20,
2203–2213.
Tanganelli, S., Sandager-Nielsen, K.,
Ferraro, L., Antonelli, T., Kehr, J.,
Franco, R., Ferré, S., Agnati, L.
F., Fuxe, K., and Scheel-Krüger,
J. (2004). Striatal plasticity at the
network level. Focus on adeno-
sine A2A and D2 interactions
in models of Parkinson’s dis-
ease. Parkinsonism Relat. Disord. 10,
273–280.
Tebano, M. T., Martire, A., Chiodi, V.,
Pepponi, R., Ferrante, A., Domenici,
M. R., Frank, C., Chen, J. F., Ledent,
C., and Popoli, P. (2009). Adenosine
A2A receptors enable the synaptic
effects of cannabinoidCB1 receptors
in the rodent striatum. J.Neurochem.
110, 1921–1930.
Tozzi, A., de Iure, A., Di Filippo, M.,
Tantucci, M., Costa, C., Borsini, F.,
Ghiglieri,V.,Giampà,C., Fusco,F. R.,
Picconi, B., and Calabresi, P. (2011).
The distinct role of medium spiny
neurons and cholinergic interneu-
rons in the D2/A2A receptor inter-
action in the striatum: implications
for Parkinson’s disease. J. Neurosci.
31, 1850–1862.
Woods, A. S., and Ferré, S. (2005). The
amazing stability of the arginine-
phosphate electrostatic interaction.
J. Proteome Res. 4, 1397–1402.
Yao, L., Fan, P., Jiang, Z., Mailliard, W.
S., Gordon, A. S., and Diamond,
I. (2003). Addicting drugs utilize a
synergistic molecular mechanism in
common requiring adenosine and
Gi-beta gamma dimers. Proc. Natl.
Acad. Sci. U.S.A. 100, 14379–14384.
Zoli, M., Agnati, L. F., Hedlund, P. B.,
Li, X.-M., Ferré, S., and Fuxe, K.
(1993). Receptor-receptor interac-
tions as an integrative mechanism
in nerve cells. Mol. Neurobiol. 7,
293–334.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 02 May 2011; paper pend-
ing published: 17 May 2011; accepted:
08 June 2011; published online: 17 June
2011.
Citation: Ferré S,QuirozC,OrruM,Gui-
tart X, Navarro G, Cortés A, Casadó V,
Canela EI, Lluis C and Franco R (2011)
Adenosine A2A receptors and A2A recep-
tor heteromers as key players in striatal
function. Front. Neuroanat. 5:36. doi:
10.3389/fnana.2011.00036
Copyright © 2011 Ferré, Quiroz, Orru,
Guitart, Navarro, Cortés, Casadó,
Canela, Lluis and Franco. This is an
open-access article subject to a non-
exclusive license between the authors
and Frontiers Media SA, which permits
use, distribution and reproduction in
other forums, provided the original
authors and source are credited and other
Frontiers conditions are complied with.
Frontiers in Neuroanatomy www.frontiersin.org June 2011 | Volume 5 | Article 36 | 8
